Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MetaVia ( (MTVA) ) has shared an update.
MetaVia Inc. announced positive results from its Phase 2a clinical trial of DA-1241 in patients with presumed MASH, demonstrating significant improvements in liver enzymes and glucose levels. The trial’s success suggests DA-1241 could be a safe and effective treatment option for MASH, with further studies and an FDA meeting planned for 2025.
More about MetaVia
MetaVia Inc., a clinical-stage biotechnology company, is focused on transforming cardiometabolic diseases.
YTD Price Performance: -39.24%
Average Trading Volume: 41,295
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $19.37M
See more insights into MTVA stock on TipRanks’ Stock Analysis page.